Mo, good post and agreed 100%. I believe this is the first time Leo uses the phrase “complete licensing deals”. It gives me the impression that the signed term sheet is still active and the partner is waiting for the result of the EOP meeting to close a deal. Also glad to see P is back in the picture.

Quote:

---

”A successful End-of-Phase 2 FDA meeting for our Brilacidin-Oral Mucositis asset, or positive results from our Phase 2b Prurisol trial in psoriasis—either outcome we believe would open up enormous possibilities for our shareholders,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.

---

http://www.ipharminc.com/press-release/2018/1...priorities